METASTATIC MALIGNANT SOLID NEOPLASM
Clinical trials for METASTATIC MALIGNANT SOLID NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new METASTATIC MALIGNANT SOLID NEOPLASM trials appear
Sign up with your email to follow new studies for METASTATIC MALIGNANT SOLID NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Radiation and new drug combo tested to fight spreading cancers
Disease control TerminatedThis early-phase trial tested the safety and initial effectiveness of a new immunotherapy drug (BMS-986218), given alone or with another immunotherapy drug (nivolumab), alongside targeted radiation therapy. It was for adults with advanced solid cancers that had spread to other pa…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Two-Pronged attack tested against brain tumors
Disease control TerminatedThis early-phase study tested a combination of two drugs, bintrafusp alfa and pimasertib, for patients with cancer that had spread to the brain (brain metastases). The goal was to find a safe dose and see if the combination could help control the brain tumors and help patients li…
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New hope: testing powerful cancer drugs for people with HIV
Disease control TerminatedThis early-stage study tested the safety and best dose of two immunotherapy drugs, nivolumab and ipilimumab, for people living with HIV who also have advanced cancers like Hodgkin lymphoma, Kaposi sarcoma, or lung cancer. The goal was to see if these drugs, which help the immune …
Matched conditions: METASTATIC MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC